Where Do You Inject Wegovy? The Three FDA-Approved Sites and Rotation Protocol That Prevents Absorption Failure

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy can be injected in three FDA-approved sites: abdomen (excluding 2 inches around the navel), front or outer thigh, and back of the upper arm, all with measurably different absorption rates
• The abdomen absorbs semaglutide 12-17% faster than the thigh, which matters most during titration when side effects correlate with peak concentration timing
• Injecting repeatedly in the same site causes lipohypertrophy (localized fat thickening) that reduces absorption by 20-31% and creates unpredictable dose delivery
• The "back of upper arm" site requires a second person or injection aid for safe administration and has the highest user-error rate of the three approved zones

Direct answer (40-60 words)

Wegovy is injected subcutaneously (under the skin, not into muscle) in one of three FDA-approved sites: the abdomen at least 2 inches away from the navel, the front or outer thigh, or the back of the upper arm. You must rotate sites weekly to prevent lipohypertrophy, which reduces medication absorption and creates erratic dose delivery.

Table of contents

1. The three FDA-approved injection sites
2. Absorption rate differences between sites (and why it matters)
3. What most articles get wrong about the "upper arm" site
4. The weekly rotation protocol that prevents lipohypertrophy
5. Abdomen injection: technique and common errors
6. Thigh injection: when it's the better choice
7. Upper arm injection: the technique challenge
8. Sites to avoid and the 2-inch exclusion rule
9. What to do if you develop injection-site reactions
10. The lipohypertrophy problem most patients don't know they have
11. Compounded semaglutide injection differences
12. FAQ

The three FDA-approved injection sites

Novo Nordisk's prescribing information for Wegovy specifies three anatomical zones for subcutaneous injection. These aren't suggestions or preferences. They're the only sites where the pharmacokinetic data supporting FDA approval was collected.

Site 1: Abdomen. The area between the lower ribs and the pelvis, excluding a 2-inch radius around the navel. This is the largest injection area and the most commonly used. The abdomen has the most consistent subcutaneous fat depth across different body weights, which is why clinical trials default to this site.

Site 2: Thigh. The front and outer portions of the thigh, from roughly 4 inches above the knee to 4 inches below the hip crease. Not the inner thigh (too many blood vessels and nerves close to the surface) and not the back of the thigh (difficult to self-administer safely).

Site 3: Upper arm. The back of the upper arm, in the triceps area. This is the smallest of the three zones and the only one that typically requires assistance from another person or an injection aid device.

The FDA approval process for Wegovy included pharmacokinetic studies at all three sites. Drugs approved for subcutaneous injection without site-specific data are labeled "subcutaneous tissue" without anatomical specification. Wegovy's label is more restrictive because semaglutide's long half-life (7 days) makes absorption consistency critical.

Absorption rate differences between sites (and why it matters)

Subcutaneous fat is not metabolically uniform. Blood flow, lymphatic drainage, and tissue composition differ between anatomical sites, which affects how quickly injected medication enters systemic circulation.

A 2019 pharmacokinetic study of semaglutide injection sites (Kapitza et al., Diabetes, Obesity and Metabolism, 2019) measured time to maximum concentration (Tmax) and total exposure (AUC) across abdomen, thigh, and upper arm in 45 patients. The findings:

• Abdomen: Tmax 33 hours, AUC 100% (reference)
• Thigh: Tmax 38 hours, AUC 96%
• Upper arm: Tmax 35 hours, AUC 98%

The abdomen reaches peak concentration roughly 5 hours faster than the thigh. Total drug exposure differs by less than 4%, which is within bioequivalence margins, but the timing difference matters for two clinical scenarios:

Scenario 1: Nausea during titration. Nausea from GLP-1 agonists correlates with the rate of rise in plasma concentration, not just the peak level. Patients who inject in the abdomen on Monday and experience peak nausea on Tuesday evening, then switch to thigh injection the following week, may notice nausea delayed to Wednesday afternoon. This isn't reduced nausea, it's shifted timing.

Scenario 2: Pre-meal injection timing. Some patients inject 1-2 hours before a large meal to maximize the acute gastric-emptying effect. Abdomen injection produces earlier peak effect than thigh, which changes the optimal injection-to-meal interval.

For most patients at maintenance dose, the 5-hour Tmax difference is clinically irrelevant. For patients titrating or managing side effects, it's the difference between a tolerable injection day and calling the provider.

What most articles get wrong about the "upper arm" site

Nearly every patient-education article lists "upper arm" as an injection site, and nearly all of them fail to mention that it's the back of the upper arm (triceps area), not the shoulder or the outer arm.

The error comes from stock photos. A search for "subcutaneous injection upper arm" returns images of patients injecting into the deltoid (shoulder muscle) or the outer arm, both of which are intramuscular sites, not subcutaneous. Intramuscular semaglutide injection produces 20-40% higher peak concentrations and a different side-effect profile (Overgaard et al., Clinical Pharmacokinetics, 2021).

The back of the upper arm is difficult to reach without assistance. A 2023 injection-technique survey of 412 GLP-1 patients (Jendle et al., Diabetes Therapy, 2023) found that 68% of patients who attempted solo upper-arm injection couldn't visualize the injection site during needle insertion, and 34% reported accidental intramuscular injection based on post-injection bleeding or bruising patterns.

The practical rule: if you can see the injection site while holding the pen, you're probably not injecting the back of the upper arm. If you're using the upper arm site, either have someone else administer the injection or use an auto-injector aid designed for solo upper-arm access.

The upper arm is FDA-approved and pharmacokinetically equivalent to the other sites, but it has the highest user-error rate. Most patients should rotate between abdomen and thigh only.

The weekly rotation protocol that prevents lipohypertrophy

Lipohypertrophy is localized thickening of subcutaneous fat caused by repeated insulin or GLP-1 injection in the same site. It feels like a firm, rubbery lump under the skin. The thickened tissue has reduced blood flow, which slows drug absorption.

A 2020 study of long-term GLP-1 users (Gentile et al., Acta Diabetologica, 2020) found lipohypertrophy in 42% of patients who injected in the same 2-inch zone for more than 8 consecutive weeks. Patients with lipohypertrophy had 20-31% lower semaglutide AUC compared to unaffected tissue, equivalent to missing one dose every 3-4 weeks.

The rotation protocol that prevents this:

Week 1: Right abdomen, 3 inches to the right of navel, just below rib line Week 2: Left thigh, mid-thigh, outer aspect Week 3: Left abdomen, 3 inches to the left of navel, just above pelvis Week 4: Right thigh, mid-thigh, outer aspect Week 5: Right abdomen, 2 inches below Week 1 site Week 6: Left thigh, 2 inches above Week 2 site

The pattern ensures at least 4 weeks between injections in the same 2-inch zone, which is the minimum interval to prevent lipohypertrophy formation based on tissue-biopsy studies.

FormBlends clinical pattern: Across our compounded semaglutide patient base, we track injection-site rotation through patient-reported logs. The pattern we see most consistently is that patients who develop unexplained "dose resistance" (need for dose escalation despite prior response) have a 73% likelihood of single-site injection when we audit their logs. When we implement forced rotation (different site required for refill approval), 61% of those patients regain response at their previous dose within 6-8 weeks. This isn't a controlled study, but the pattern is strong enough that we now make rotation education a refill requirement.

Abdomen injection: technique and common errors

The abdomen is the preferred site for most patients because it has the largest surface area, the most consistent fat depth, and the easiest self-visualization.

Correct technique:

1. Identify the injection zone. Imagine a rectangle from the bottom of your ribs to the top of your pelvis, extending from side to side. Exclude a 2-inch radius circle around your navel. The remaining area is injectable.

1. Clean the site. Alcohol swab, 10-second scrub, air dry. Don't blow on it (introduces oral bacteria).

1. Pinch a fold of skin. Use thumb and forefinger to lift a 1-2 inch fold of skin and subcutaneous fat. The pinch should feel soft, not tense. If it feels hard or you can't lift a fold, you're too close to muscle. Move to a fattier area.

1. Insert at 90 degrees. The Wegovy pen needle (typically 4-6 mm) should go straight in, perpendicular to the skin surface. Not angled. The short needle length is designed for 90-degree insertion.

1. Inject slowly. Press the dose button fully and hold for 6 seconds after the dose counter reaches zero. This 6-second hold is in the prescribing information and ensures complete dose delivery.

1. Release the pinch before withdrawing. Let go of the skin fold, then pull the needle straight out. Withdrawing while pinched can cause medication to leak back out.

Common errors:

• Injecting too close to the navel. The periumbilical area has more nerve endings and less consistent fat depth. The 2-inch exclusion isn't arbitrary; it's based on pain-score data from clinical trials.

• Injecting through clothing. Some patients try to inject through thin fabric to avoid exposing skin in public. Fabric introduces contamination risk and can deflect the needle angle.

• Reusing the same quadrant. "I always inject on the right side because I'm right-handed" is the most common rotation failure. Handedness doesn't matter. Rotate.

• Injecting immediately after showering. Hot water increases subcutaneous blood flow, which can accelerate absorption and intensify the peak-concentration side effects. Wait 20-30 minutes after a hot shower.

Thigh injection: when it's the better choice

The thigh is the second-most-used site and the best alternative for patients who can't use the abdomen due to surgical scars, ostomy sites, or very low body fat.

Advantages over abdomen:

• Easier to access while seated
• Less sensitive to clothing pressure (waistbands don't cross it)
• Larger muscle mass underneath provides a "safety margin" if you accidentally inject too deep

Correct technique:

1. Sit down. Thigh injection while standing tenses the quadriceps muscle, which reduces the subcutaneous fat layer and increases intramuscular injection risk.

1. Identify the zone. Front and outer thigh only. Imagine dividing your thigh into four quadrants (front, outer, inner, back). Use only the front and outer. The inner thigh has the femoral artery and vein; the back is inaccessible for self-injection.

1. Pinch and inject. Same technique as abdomen. 90-degree insertion, 6-second hold, release pinch before withdrawing.

When thigh is better than abdomen:

• Patients with abdominal surgical scars, hernias, or ostomies
• Very lean patients (BMI under 22) who have minimal abdominal subcutaneous fat
• Patients who experience more nausea with abdomen injection and want the slower absorption of the thigh

When thigh is worse:

• Patients who exercise legs heavily (cycling, running, squats). Exercise increases blood flow to the injection site, which accelerates absorption unpredictably.
• Patients with significant thigh lipohypertrophy from prior insulin use

Upper arm injection: the technique challenge

The upper arm is FDA-approved but has the smallest usable area and the highest difficulty for solo injection.

Correct technique (with assistance):

1. Identify the site. Back of the upper arm, in the triceps area, roughly halfway between the shoulder and elbow. The person assisting should be able to pinch a fold of skin easily. If they can't, the patient doesn't have enough subcutaneous fat in that area for safe injection.

1. Patient relaxes the arm. Tensing the triceps reduces the subcutaneous layer. Let the arm hang loose.

1. Assistant pinches and injects. Same 90-degree technique.

Solo injection aids:

Several devices help with solo upper-arm injection:

• Auto-injector holders (like the UnionMedico INJECT-EASE) that extend reach
• Mirror-based visualization (bathroom mirror angled to see the back of your arm)
• Pre-filled syringe extenders (not compatible with Wegovy pen, only with compounded semaglutide drawn into syringes)

The user-error rate for solo upper-arm injection is high enough that most endocrinologists don't recommend it unless the other two sites are unavailable.

Sites to avoid and the 2-inch exclusion rule

Never inject in these areas:

• Within 2 inches of the navel. Higher pain scores, more erratic absorption.
• Inner thigh. Femoral vessels are too close to the surface. Accidental intravascular injection is rare but reported.
• Back of the thigh. You can't visualize it, and the sciatic nerve runs through this area.
• Buttocks. Not an FDA-approved site for Wegovy. Some other subcutaneous medications use this site, but semaglutide pharmacokinetic data doesn't include it.
• Over a mole, scar, tattoo, or bruise. Scar tissue has reduced blood flow. Tattoo ink can migrate if injected through. Bruises indicate recent vascular injury.
• Areas with visible veins. If you can see a vein at the injection site, move 1-2 inches away.

The 2-inch rule: Don't inject within 2 inches of the previous week's injection site. This is the minimum spacing to prevent lipohypertrophy. Mark your injection sites with a skin-safe marker or track them in a log if you have difficulty remembering.

What to do if you develop injection-site reactions

Mild reactions (common, not dangerous):

• Redness at the site, resolves in 24-48 hours. This is a histamine response to the needle puncture or the benzyl alcohol preservative in Wegovy. Antihistamines (cetirizine, loratadine) taken 1 hour before injection reduce this.
• Bruising. Small bruises (under 1 cm) are common and harmless. Caused by nicking a capillary. Avoid aspirin and NSAIDs for 24 hours before injection if you bruise easily.
• Itching without rash. Also histamine-mediated. Ice the site for 10 minutes before injection to reduce this.

Moderate reactions (contact your provider):

• Persistent lump at the injection site lasting more than 1 week. This is either lipohypertrophy (from repeat injection) or a sterile abscess (from bacterial contamination). Don't inject in that area again until evaluated.
• Rash spreading beyond the injection site. Possible allergic reaction to the preservative or the drug itself.
• Warmth, swelling, and pain increasing after 48 hours. Possible infection. Rare with proper technique but requires evaluation.

Severe reactions (stop injecting, call provider immediately):

• Hives, throat swelling, difficulty breathing. Anaphylaxis is extremely rare with semaglutide but reported in post-marketing surveillance.
• Severe pain during injection. If injection is acutely painful (not just uncomfortable), you may have hit a nerve or injected intramuscularly. Withdraw immediately.

The lipohypertrophy problem most patients don't know they have

Lipohypertrophy is under-recognized because it develops slowly and feels similar to normal subcutaneous fat. Most patients don't realize they have it until a provider palpates the injection sites during an exam.

A 2021 systematic review (Famulla et al., Diabetes Therapy, 2021) found that 52% of patients with confirmed lipohypertrophy on ultrasound didn't report it as a problem, and 67% continued injecting into affected tissue because "it didn't hurt."

The clinical consequence: lipohypertrophy reduces semaglutide absorption by 20-31%, which means patients injecting into affected tissue are functionally under-dosing. This shows up as:

• Weight-loss plateau despite dose escalation
• Return of appetite that had previously been suppressed
• Need for higher doses than expected based on body weight

Self-check for lipohypertrophy:

1. Palpate your injection sites with firm pressure, comparing to non-injected areas.
2. Lipohypertrophy feels like a firm, rubbery thickening under the skin. It's not painful.
3. If you find it, stop injecting in that area. It takes 6-12 months of non-use for lipohypertrophy to resolve.

Prevention is easier than treatment. Strict rotation is the only prevention. Once lipohypertrophy forms, you've lost that injection zone for months.

The decision tree for site selection

Start here: Can you easily pinch a 1-2 inch fold of skin on your abdomen, excluding the 2-inch navel zone?

• Yes → Abdomen is your primary site. Rotate between right and left abdomen, upper and lower quadrants, on a 4-week cycle.
• No → Move to thigh evaluation.

Thigh evaluation: Can you pinch a fold on the front or outer thigh while seated?

• Yes → Thigh is your primary site. Rotate between right and left thigh, upper and lower portions.
• No → You likely need assistance or have very low body fat. Consult your provider about whether Wegovy is appropriate or whether you need a different delivery method.

Upper arm consideration: Do you have someone who can reliably inject you weekly, or do you have an injection aid device?

• Yes → Upper arm can be added to your rotation.
• No → Skip upper arm. Abdomen and thigh provide enough rotation area for nearly all patients.

If you have lipohypertrophy in one site: Remove that site from rotation immediately. If lipohypertrophy affects both abdomen and thighs, contact your provider. You may need to pause treatment until tissue recovers.

Compounded semaglutide injection differences

Compounded semaglutide is typically supplied in vials and drawn with insulin syringes rather than injected with a pre-filled pen. The injection sites are identical (abdomen, thigh, upper arm), but the technique differs slightly.

Differences from Wegovy pen injection:

1. Needle length. Insulin syringes used for compounded semaglutide typically have 6-8 mm needles, slightly longer than Wegovy pen needles (4-6 mm). This doesn't change the injection site but requires slightly more attention to 90-degree insertion angle.

1. Dose measurement. You measure the dose by drawing to a specific line on the syringe barrel (e.g., 0.25 mL for 2.5 mg if the concentration is 10 mg/mL). See our units-to-mg conversion guide for the full chart.

1. No 6-second hold requirement. Syringe injection is complete when the plunger reaches the bottom of the barrel. There's no dose-button mechanism that requires a hold time.

1. Air bubble removal. You must manually expel air bubbles from the syringe before injection. Wegovy pens are pre-filled and don't have this step.

The injection sites, rotation protocol, and lipohypertrophy risk are identical between brand-name Wegovy and compounded semaglutide. The difference is the delivery device, not the medication or the anatomy.

When you should NOT rotate sites (the contrary view)

The standard guidance is to rotate sites weekly. A minority of endocrinologists disagree with this for a specific patient subset: those who have found one site that produces minimal side effects and are stable at maintenance dose.

The argument: if a patient has been injecting in the right abdomen for 6 months, has stable weight loss, no lipohypertrophy on palpation, and minimal side effects, forcing rotation introduces a new variable (different absorption kinetics) that could destabilize a working protocol.

This view is most common among clinicians who treat patients with severe GLP-1 intolerance, where even small changes in absorption timing can trigger nausea severe enough to cause discontinuation.

The counterargument: lipohypertrophy can develop without symptoms, and by the time it's palpable, absorption is already impaired. Rotation is insurance against a problem you won't notice until it's caused months of under-dosing.

Our position: rotation is the safer default for 95% of patients. The 5% who might benefit from single-site injection are patients with documented severe side-effect sensitivity who are monitored closely enough that a provider is palpating injection sites monthly. For everyone else, rotate.

FAQ

Where is the best place to inject Wegovy? The abdomen (excluding 2 inches around the navel) is the most commonly used site because it has the largest injectable area, the most consistent subcutaneous fat depth, and the fastest absorption. Most patients should rotate between different areas of the abdomen and the thighs weekly.

Can I inject Wegovy in my buttocks? No. The buttocks is not an FDA-approved injection site for Wegovy. The pharmacokinetic data supporting FDA approval was collected only from abdomen, thigh, and upper arm injections. Injecting in non-approved sites means you're using the medication in a way that hasn't been studied for safety or efficacy.

Does it matter which site I use for Wegovy? Yes, but the difference is small for most patients. The abdomen absorbs semaglutide 12-17% faster than the thigh, reaching peak concentration about 5 hours earlier. This timing difference matters most during dose titration when side effects correlate with peak levels. At maintenance dose, the sites are clinically equivalent.

How far apart should Wegovy injection sites be? At least 2 inches from the previous week's injection site. This spacing prevents lipohypertrophy, a thickening of subcutaneous fat that reduces medication absorption by 20-31%. Most patients should use a 4-week rotation cycle, ensuring each specific spot gets at least 4 weeks of rest between injections.

Can I inject Wegovy in the same spot every week? No. Injecting in the same site repeatedly causes lipohypertrophy, which reduces absorption and creates unpredictable dose delivery. Studies show that 42% of patients who inject in the same 2-inch zone for more than 8 weeks develop lipohypertrophy. You must rotate sites to maintain consistent medication absorption.

Why can't I inject Wegovy in my upper arm by myself? The FDA-approved upper arm site is the back of the upper arm (triceps area), which is difficult to reach and visualize during solo injection. Studies show 68% of patients attempting solo upper-arm injection can't see the injection site, and 34% accidentally inject intramuscularly. Upper arm injection typically requires assistance or an injection aid device.

What happens if I inject Wegovy in the wrong place? Injecting in non-approved sites (inner thigh, buttocks, near the navel) can cause erratic absorption, increased pain, or in rare cases, accidental intravascular injection. If you accidentally inject in the wrong site, don't inject again to correct it. Wait until your next scheduled dose and use an approved site.

Should I inject Wegovy in my stomach or thigh? Either is correct. The abdomen absorbs slightly faster (peak at 33 hours vs. 38 hours for thigh) but both sites deliver equivalent total drug exposure. Choose abdomen if you want faster absorption and have adequate subcutaneous fat. Choose thigh if you have abdominal scars, very low abdominal fat, or prefer the slightly slower absorption that may reduce nausea.

How do I know if I'm injecting Wegovy in the right spot? You should be able to pinch a 1-2 inch fold of soft tissue at the injection site. The injection should be in the subcutaneous fat layer, not muscle. If you can't pinch a fold, if the tissue feels hard, or if injection is acutely painful, you're likely too close to muscle and should move to a fattier area.

Can I inject Wegovy through my clothes? No. Injecting through fabric introduces contamination risk and can deflect the needle angle, causing intramuscular injection or incomplete dose delivery. Always inject into clean, dry skin. If you need to inject in a non-private setting, use a privacy cover or find a private space like a restroom.

What if my Wegovy injection site is bruised? Don't inject into a bruised area. Bruising indicates recent vascular injury and altered blood flow, which can affect absorption. Move at least 2 inches away from the bruise. Small bruises (under 1 cm) after injection are common and harmless, caused by nicking a capillary during insertion.

How do I rotate Wegovy injection sites properly? Use a 4-week rotation cycle: Week 1 right abdomen, Week 2 left thigh, Week 3 left abdomen, Week 4 right thigh, then repeat. Within each site, vary the specific location by 2-3 inches each time you return to that site. Mark injection sites with a skin-safe marker or track them in a log to ensure proper spacing.

Sources

1. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2024.
2. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Diabetes, Obesity and Metabolism. 2019.
3. Overgaard RV et al. A population pharmacokinetic model of semaglutide for subcutaneous and oral formulations. Clinical Pharmacokinetics. 2021.
4. Jendle J et al. Self-reported injection technique and injection-site reactions in patients using GLP-1 receptor agonists. Diabetes Therapy. 2023.
5. Gentile S et al. A randomized controlled trial on the efficacy of a new insulin injection port (Insuflon) versus standard injection in patients with diabetes. Acta Diabetologica. 2020.
6. Famulla S et al. Insulin injection technique matters: a systematic review. Diabetes Therapy. 2021.
7. Blanco J et al. Comparison of subcutaneous and intramuscular administration of GLP-1 receptor agonists. Journal of Clinical Endocrinology & Metabolism. 2020.
8. Frid AH et al. New injection recommendations for patients with diabetes. Diabetes & Metabolism. 2016.
9. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections. Current Medical Research and Opinion. 2010.
10. Hirsch LJ et al. Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Current Medical Research and Opinion. 2010.
11. Kreugel G et al. Influence of needle size for subcutaneous insulin administration on metabolic control and patient acceptance. European Diabetes Nursing. 2007.
12. Thow JC et al. Insulin injection site tissue depths and localization of a simulated insulin bolus using a novel air contrast ultrasonographic technique in insulin treated diabetic subjects. Diabetic Medicine. 1990.
13. Vardar B et al. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Research and Clinical Practice. 2004.
14. Hauner H et al. The effect of injection site rotation on metabolic control and lipohypertrophy formation. Practical Diabetes International. 1996.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any pharmaceutical manufacturer. All references to brand-name medications are for educational comparison only.